Ekso Bionics receives Nasdaq bid price deficiency notice; has until June 10, 2025 to comply

EKSO BIONICS HOLDINGS, INC.

Nasdaq notice dated Dec 12, 2024: common stock bid price below $1.00 for 31 consecutive business days.
Company has 180 calendar days, until June 10, 2025, to regain compliance under Nasdaq Listing Rule 5810(c)(3)(A).
To regain compliance, closing bid price must be $1.00 or more for at least ten consecutive business days.
If not cured by June 10, 2025, Company may seek a second 180-day period if meeting all other initial listing standards and intends a reverse stock split.
Failure to regain compliance or secure extension could result in delisting from Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.